Verbatim response from Perplexity
No telehealth services can legally or reliably offer compounded GLP-1s in the current FDA enforcement environment, as the agency has explicitly banned their marketing as substitutes for approved drugs and issued over 55 warning letters to companies (including Hims & Hers, SkinnyRx, and Join Josie) for misleading claims about these products[1][3][4].
Key details explaining why no service currently offers them:
| Factor | Impact on Telehealth Services |
|---|---|
| FDA Enforcement | The FDA has resumed aggressive, batch-style enforcement targeting telehealth marketing of compounded GLP-1s, issuing 25 warning letters in June 2026 and 30 in March 2026[1][3] |
| Legal Status | Compounded GLP-1s are not FDA-approved and have not undergone rigorous safety, efficacy, or quality review[1] |
| Company Actions | Major providers like Hims & Hers have been referred to the Department of Justice and face restricted access to GLP-1 ingredients[9][4] |
| FDA Stance | The agency views compounded GLP-1s as "knockoff drugs" that pose significant safety risks and prohibits marketing them as equivalent to Ozempic, Wegovy, or Mounjaro[1][4] |
Recommendation for patients:
Instead of seeking compounded GLP-1s, consult legitimate telehealth providers that offer FDA-approved GLP-1 medications (e.g., semaglutide for Ozempic/Wegovy, tirzepatide for Mounjaro) through verified pharmacy networks. Providers like Hims & Hers (despite enforcement actions) still offer FDA-approved alternatives, and established services such as Ro (Roman Health), Cure, and Plural provide access to approved GLP-1s via licensed pharmacies[4]. Compounded versions should only be used when a patient's medical needs cannot be met by FDA-approved drugs, per HHS guidelines[4].